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Background: In the coBRIM study, cobimetinib plus vemurafenib (CþV) significantly improved survival outcomes vs placebo and
vemurafenib (PþV) in patients with advanced/metastatic BRAFV600-mutated melanoma. An analysis of health-related quality of life
(HRQOL) from coBRIM is reported.
Methods: Patients completing the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire
Core 30 (QLQ-C30) at baseline and X1 time point thereafter constituted the analysis population. Change from baseline X10
points was considered clinically meaningful.
Results:Mean baseline scores for all QLQ-C30 domains were similar between arms. Most on-treatment scores for QLQ-C30 domains
were also comparable between arms. A transient deterioration in role function in cycle 1day 15 (C1D15; -14.7 points) in the PþV arm
and improvement in insomnia in the CþV arm at C2D15 (-12.4 points) was observed. Among patients who experienced aX10-point
change from baseline (responders), between-group differences were greatest for insomnia (16%), social functioning (10%), fatigue (9%)
and pain (7%), all favouring CþV. Diarrhoea, photosensitivity reaction, pyrexia, and rash did not meaningfully affect global health
status (GHS). Serous retinopathy was associated with a transient decrease in GHS at C1D15 assessment.
Conclusions: In patients with advanced/metastatic BRAFV600-mutated melanoma, treatment with CþV maintained HRQOL
compared with PþV, with superior efficacy.
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The combination of cobimetinib (a MEK inhibitor) and vemur-
afenib (a BRAF inhibitor) has been shown to significantly improve
clinical outcomes in patients with BRAFV600 mutation–positive
unresectable locally advanced or metastatic melanoma. In the
phase III coBRIM study, cobimetinib combined with vemurafenib
significantly improved investigator-assessed progression-free sur-
vival (PFS) compared with placebo and vemurafenib in this patient
population (median PFS, 9.9 vs 6.2 months; hazard ratio¼ 0.51;
95% confidence interval (CI): 0.39–0.68; Po0.001 (data cutoff May
2014; database lock 10 July 2014)) (Larkin et al, 2014).
In addition to efficacy benefits, both tolerability of treatment
and health-related quality of life (HRQOL) are important
considerations for patients. Accordingly, we evaluated patient-
reported outcomes (PROs), including symptoms, functional
impact, and HRQOL, in patients participating in the coBRIM
study using the European Organisation for Research and Cancer
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30;
Aaronson et al, 1993). The EORTC QLQ-C30, a validated, self-
reported measure, consists of 30 items which assess five functional
domains (physical, role, cognitive, emotional, and social), global
health status (GHS), and various general cancer symptoms.
This report is based on the data cutoff of the aforementioned
primary PFS analysis (May 2014). At the time of the data cutoff,
cobimetinib combined with vemurafenib was associated with a
similar incidence of any-grade adverse events (AEs) compared with
placebo and vemurafenib (98% of patients in each arm). The rate
of treatment discontinuation because of AEs was also similar in
both arms (13% in the cobimetinib combined with vemurafenib
arm and 12% in the placebo and vemurafenib arm) (Larkin et al,
2014). However, certain AEs, including diarrhoea, photosensitivity,
pyrexia, rash, and serous retinopathy, occurred more frequently
with this combination regimen, and were of clinical interest.
Therefore, the objectives of these analyses were twofold: to evaluate
the impact of treatment with cobimetinib combined with
vemurafenib on patient HRQOL compared with placebo and
vemurafenib, and to explore the impact of select symptomatic AEs
on HRQOL in the treatment arm.
MATERIALS AND METHODS
Study design and treatment. The coBRIM study (NCT01689519)
was a global multicentre, randomised, double-blind, placebo-
controlled phase III trial designed to evaluate the safety and
efficacy of cobimetinib in combination with vemurafenib, com-
pared with placebo and vemurafenib, in patients with BRAFV600
mutation–positive unresectable locally advanced or metastatic
melanoma. Patient eligibility criteria have previously been
described (Larkin et al, 2014). Key eligibility criteria included age
Z18 years, histologically confirmed unresectable locally advanced
stage IIIC or IV melanoma, BRAFV600 mutation detected using the
cobass 4800 BRAF V600 Mutation Test (Roche Molecular
Systems Inc, Indianapolis, IN, USA), no prior systemic therapy
for advanced disease, and Eastern Cooperative Oncology Group
performance status (ECOG PS) 0 or 1.
Patients were randomly assigned in a 1:1 ratio to receive oral
vemurafenib (960mg twice daily) in combination with either
placebo or oral cobimetinib (60mg once daily for 21 days followed
by 7 days off; 21/7). Treatment was administered in 28-day cycles
and continued until disease progression, unacceptable toxicity, or
withdrawal of consent. A prespecified secondary end point was to
compare HRQOL between treatment arms, as measured by the
GHS scale within the EORTC QLQ-C30. The study was approved
by the institutional review board or ethics committee at each
participating institution and was conducted in accordance with the
provisions of the Declaration of Helsinki and the International
Conference on Harmonisation guidelines for Good Clinical
Practice. All patients provided written informed consent.
HRQOL assessments. Disease and treatment-related symptoms,
functioning, and HRQOL were evaluated using the EORTC QLQ-
C30 (Aaronson et al, 1993). Functional domains and symptom-
related items are measured over the previous week on a 4-point
scale, ranging from ‘not at all’ to ‘very much’. The GHS 2-item
scale is intended to measure HRQOL and requests patients to select
the number (1–7) that best applies to them in terms of their overall
health as well as their ‘overall quality of life’ during the past week.
For GHS and functioning scales, an increase in scores indicates
improvement, whereas a decrease in scores indicates improvement
for symptom scales or items.
The EORTC QLQ-C30 was administered at baseline, days 1 and
15 in cycles 1 and 2, and every second cycle thereafter until patient
withdrawal or end of study. Questionnaires were collected using
electronic tablets and data were transmitted directly into the study
database. Missing values were not imputed. Data were evaluable
through cycle 8 day 1, after which too few patients remained to
allow for meaningful conclusions (o25% of the baseline cohort).
Change of X10 points from baseline in any scale (GHS,
functioning, or symptoms) was considered clinically meaningful
(Osoba et al, 1998).
Statistical analysis. Patients who completed a PRO assessment at
baseline and at least one time point after baseline were defined as
the PRO-evaluable population and were included in the analysis.
The PRO end points were not part of formal statistical testing and
the study was not powered to detect differences between treatment
arms.
We reported descriptively the mean change from baseline scores
for each EORTC QLQ-C30 scale at each assessment time point by
treatment arm. Additionally, repeated-measures mixed-effects
models were also constructed for the comparison of the EORTC
QLQ-C30 GHS, function, and symptom scores between treatment
arms, to provide a summary statistical measure of longitudinal
change. Each model had a term for intercept, a term for a linear
time trend (in weeks), a term for treatment group, a term for
treatment-by-time interaction, and stratification factors, including
geographic region and metastasis classification. Repeated measures
over time were accounted for by an exchangeable covariance
structure (using the REPEATED statement in SAS PROC MIXED).
A responder analysis summarised the proportion of patients in
each treatment arm who experienced clinically meaningful
improvement at X1 post-baseline assessment for each EORTC
QLQ-C30 scale (HRQOL, functional, and symptoms). A clinically
meaningful improvement was defined as aZ10-point change from
baseline within a patient’s self-rated score (Osoba et al, 1998) and
conducted for each treatment arm separately.
Post hoc analyses in the PRO population evaluated the impact of
symptomatic adverse events of special interest (i.e., pyrexia,
diarrhoea, photosensitivity, rash, and serous retinopathy) on
HRQOL by comparing mean changes from baseline in the GHS
score for patients in the treatment arm who experienced each AE
(any grade) at any time point during the study and for patients in
the treatment arm who did not experience the AE at each time
point through cycle 8 day 1.
RESULTS
Patient population. Between January 2013 and January 2014, a
total of 495 patients were enrolled at 133 sites in 19 countries and
randomly assigned to receive first-line treatment with cobimetinib
combined with vemurafenib (n¼ 247) or placebo and vemurafenib
(n¼ 248). Baseline demographics and disease characteristics have
previously been described and were generally well-balanced across
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treatment groups (Larkin et al, 2014). Briefly, the majority of
patients were white (93%), male (58%), had an ECOG PS of 0
(70%), and an M1c disease stage at baseline (60%).
On the data cutoff date (9 May 2014), the PRO-evaluable
population included 420 patients (211 in the cobimetinib
combined with vemurafenib arm and 209 in the placebo and
vemurafenib arm), or 85% of the intention-to-treat population.
Among the PRO-evaluable population, completion rates of the
EORTC QLQ-C30 were 96.7% (202/209) among patients in the
placebo and vemurafenib arm and 97.2% (205/211) among patients
in the cobimetinib combined with vemurafenib arm at baseline and
consistently high (488%) for all assessments thereafter. Patients in
both treatment arms reported moderate-to-high functioning and
HRQOL, with minimal symptom burden at baseline (Figure 1).
Mean scores for all EORTC QLQ-C30 domains were similar
between treatment groups at baseline, with no differences
exceeding 5 points.
Longitudinal analyses. All function domains (Figure 2), most
patient-reported symptoms (Figure 3), and HRQOL, as assessed by
the EORTC QLQ-C30, were comparable between the two arms.
Among the function domains, the only clinically meaningful
change from baseline (X10 points) was observed in the Role
Function domain among patients receiving placebo and vemur-
afenib at cycle 1 day 15 (mean change from baseline, -14.7 points;
Figure 2). By cycle 8 day 1, there was a trend toward improvement
for the Emotional, Physical, and Social domains in patients who
received cobimetinib combined with vemurafenib and a trend
toward deterioration in patients who received placebo and
vemurafenib; however, they did not constitute a clinically mean-
ingful change (i.e., change from baseline of p10 points; Figure 2).
Among the symptom domains, a clinically meaningful improve-
ment in Insomnia was observed in patients who received
cobimetinib combined with vemurafenib at cycle 2 day 15 (mean
change from baseline, -12.4 points; Figure 3) and at cycle 4 day 1
(mean change from baseline, -10.6 points). Clinically meaningful
deterioration of diarrhoea symptoms were observed in patients
who received cobimetinib combined with vemurafenib at cycle 1
day 15 (mean change from baseline, 26.2 points, Figure 3) and
cycle 2 day 15 (mean change from baseline, 12.4 points). Patients
who received placebo and vemurafenib reported clinically mean-
ingful deterioration of fatigue at cycle 1 day 15 (mean change from
baseline, 13.1 points; Figure 3).
In the mixed-effect model analysis, there were few clinically
meaningful differences (X10 points) between the cobimetinib
combined with vemurafenib arm and the placebo and vemurafenib
arm across all functional domains (Supplementary Tables S1 and
S2). Among the symptom scales and items (Supplementary Table
S2), there was a clinically meaningful improvement in pain in the
cobimetinib combined with vemurafenib arm (difference in mean
change from baseline between arms, -10.63 points (95% CI: -15.32
to -5.95; Po0.0001 at cycle 1 day 15)); the only item favoring the
placebo and vemurafenib arm was diarrhoea (difference in mean
change from baseline between the arms, 23.24 points at cycle 1 day
15 (95% CI: 18.87–27.61; Po0.0001) and 11.75 points at cycle 2
day 15 (95% CI: 7.29–16.21; Po0.0001)).
Responder analysis. For GHS, as well as most functioning and
symptom scales, the difference in the proportion of responders in
each treatment arm was approximately o5%, indicating similarity
in HRQOL between the two treatment arms (Figure 4). The
differences between groups were greatest for insomnia (16%),
social functioning (10%), fatigue (9%), and pain (7%), all favouring
the cobimetinib combined with vemurafenib arm.
Impact of select symptomatic AEs on GHS. Diarrhoea, photo-
sensitivity, rash, pyrexia, and serous retinopathy (any grade) were
assessed for impact on patient-reported HRQOL (Figure 5). There
was no clinically meaningful deterioration at any time point in
HRQOL for four of the five AEs (exception of serous retinopathy),
as indicated by the absence of changes in GHS scores X10 points
in patients who experienced each AE during the study. Patients
who experienced serous retinopathy reported a transient but
clinically meaningful decrement in GHS early in treatment (cycle 1
day 15 assessment). However, at all later assessments, GHS was
similar to the baseline score in patients who experienced serous
retinopathy.
DISCUSSION
The primary analysis of the coBRIM study demonstrated that the
combination of cobimetinib and vemurafenib improved PFS and
objective response rates compared with placebo and vemurafenib
in patients with advanced or metastatic BRAFV600 mutation–
positive melanoma, with a manageable increase in the incidence of
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Figure 1. Mean baseline values for EORTC QLQ-C30. Error bars are standard error of mean (SEM). High positive scores in the functional domains
indicate better functional status, while high positive scores in symptom domains indicate worse symptoms. EORTC QLQ-C30=European
Organisation for Research and Cancer Quality of Life Questionnaire Core 30.
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AEs (Larkin et al, 2014). Although improved survival is
paramount, preserving patient HRQOL is a critically important
consideration in real-world practice. This double-blind study that
yielded a consistently high completion rate for the EORTC
QLQ-C30 provides a robust source of PRO data to better
understand treatment and disease burden in patients with
melanoma. Overall, the current analyses of the PRO data indicate
that cobimetinib combined with vemurafenib improves PFS and
overall survival (OS) outcomes without compromising HRQOL.
The trend towards patients’ functional deterioration (Emotional,
Physical, and Social function scores) by cycle 8 in the placebo and
vemurafenib arm is possibly reflective of the cumulative impact of
both progressive disease and treatment burden for patients
remaining on treatment past the time of median PFS (6.2 months),
as compared with patients in the cobimetinib combined with
vemurafenib arm who have not yet progressed.
Furthermore, data showed that pyrexia, diarrhoea, photosensi-
tivity, and rash (4 out of the 5 most commonly reported
symptomatic AEs associated with cobimetinib) did not impact
the patients’ overall quality of life (GHS) in a clinically meaningful
manner (X10 points) at any time point in the treatment arm. The
singular exception was among patients who experienced any-grade
serous retinopathy, who reported a clinically meaningful decre-
ment in GHS at the cycle 1 day 15 assessment. However, at all
subsequent assessments, GHS scores were similar to their baseline
score in patients who experienced serous retinopathy. Of note, the
observed worsening in patient-reported diarrhoea severity in the
combination arm only was also reflected in the clinician report
(on CTCAE) of diarrhoea AE (any grade: 56.7% vs 28%, gradeX3:
6.3% vs 0, for the combination and monotherapy arms,
respectively) (Larkin et al, 2014). Patient ratings of diarrhoea
severity underscore the temporal nature of this AE, characterised
by a relatively rapid onset of this AE within the first cycles of
treatment (median time to first onset, 0.36 months) and return to
baseline values afterwards. This pattern is consistent with safety
reporting (i.e., CTCAE gradings), with a decline in diarrhoea AE
incidence after cycle 2 (Dre´no et al, 2016, 2017), and the fact that
most severe events (gradeX3) occurred within the first three
cycles.
Temporal analyses of diarrhoea, photosensitivity, and serous
retinopathy at the primary data cutoff for the PFS analysis
(May 2014), compared with that from an extended follow-up
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Figure 2. Mean change from baseline in EORTC QLQ-C30 functional scores at each post-baseline assessment. Error bars are standard error of
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followed by a 7-day rest period. EORTC QLQ-C30=European Organisation for Research and Cancer Quality of Life Questionnaire Core 30.
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(September 2015), show that the incidence rates of all these AEs
decreased with continued treatment (Dre´no et al, 2016, 2017). This
is consistent with the observed early onset of these AEs and
subsequent resolution with clinical management thereafter (Dre´no
et al, unpublished data).
The double-blind, randomised, phase III COMBI-d study
evaluated the BRAF inhibitor dabrafenib in combination with
the MEK inhibitor trametinib (vs dabrafenib monotherapy) and
also reported the effect of the combination on HRQOL using the
EORTC QLQ-30 (Schadendorf et al, 2015). The baseline and on-
treatment HRQOL and symptom scores seen in this study are
similar to those reported with the combination of dabrafenib and
trametinib compared with dabrafenib and placebo. In coBRIM,
patients self-reported higher levels of physical functioning, role
functioning, cognitive functioning, and social functioning at
baseline compared with those enrolled in COMBI-d; therefore, it
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Figure 5. Impact of select AEs on global health status. Clinically meaningful change is defined as a X10-point change from baseline. Error bars
are standard error of mean (SEM). Each treatment cycle was 28 days, with vemurafenib administered on days 1–28 and cobimetinib administered
on days 1–21, followed by a 7-day rest period. AE=adverse event.
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is possible that it would be more challenging to demonstrate
clinically meaningful improvement from baseline in these
respective domains for patients enrolled in coBRIM.
A limitation of the current study is the use of a generic
instrument for the evaluation of HRQOL in patients with cancer
(EORTC QLQ-C30), rather than a melanoma-specific instrument.
Although the EORTC QLQ-C30 is widely validated for the
assessment of HRQOL in patients with cancer (Aaronson et al,
1993) and has been used across several trials in patients with
melanoma (Grob et al, 2014; Schadendorf et al, 2014; Grob et al,
2015; Schadendorf et al, 2015), it may not fully address issues
specific to patients with melanoma or symptomatic adverse events
associated with therapies other than chemotherapies. An EORTC-
based melanoma-specific module was recently developed and
consists of 33 scoring items, two single items, and three items
associated with clinical trials (EORTC QLQ-MEL38), but it has yet
to be validated (Winstanley et al, 2015). Future studies using
melanoma-specific instruments, and instruments that assess
treatment-related symptoms associated with the combination
therapy such as photosensitivity and rash, might provide greater
insight into the effects of treatments on HRQOL issues relevant to
patients with melanoma. Additionally, a limitation in the current
study is that patients who discontinue treatment due to an AE are
not required to continue to complete PRO assessments. However,
patients were required to complete the PRO questionnaires
immediately when entering the clinic, prior to the performance
of non-PRO assessments (including discussions regarding health
status and AEs) and prior to formal treatment discontinuation;
therefore, it is reasonable to believe that patients experiencing
higher grade AEs would have completed their PRO assessment
prior to formal treatment discontinuation and therefore their
patient-reported outcome data for that visit would reflect the
patient’s AE.
In conclusion, the combination of cobimetinib and vemurafenib
provides patient-reported symptoms, function, and HRQOL (with
the exception of diarrhoea) similar to that of placebo and
vemurafenib. These results, along with the previously reported
improved PFS, response rate, and OS (Larkin et al, 2014; Atkinson
V, 2015), suggest that cobimetinib combined with vemurafenib is a
superior treatment for patients with advanced or metastatic
BRAFV600 mutation–positive melanoma compared with vemur-
afenib alone.
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